Response criteria in oncologic imaging: Review of traditional and new criteria

Radiographics

Volumn 33, Issue 5, 2013, Pages 1323-1341

  Tirkes, Temel ^a   Hollar, Margaret A ^a   Tann, Mark ^a   Kohli, Marc D ^a   Akisik, Fatih ^a   Sandrasegaran, Kumaresan ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC IMAGING; HUMAN; INTERNATIONAL COOPERATION; METHODOLOGY; NEOPLASM; ONCOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; STANDARD;

DIAGNOSTIC IMAGING; HUMANS; INTERNATIONALITY; MEDICAL ONCOLOGY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC;

EID: 84884400552     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.335125214     Document Type: Article

References (28)

1. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979.
2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1):207-214.
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
4. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91(6):523-528.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
6. Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifcations to the RE-CIST criteria. Eur J Cancer 2009;45(2):248-260.
7. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21(13):2574-2582.
8. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantifcation of tumor responseinitial results. Radiology 2006;241(3):892-898.
9. Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 2009;50(2): 239-249.
10. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183(6):1619-1628.
11. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759.
12. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(suppl 5):S60-S65.
13. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(suppl 2):4-7.
14. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. RadioGraphics 2006;26(2):481-495.
15. van der Veldt AA, Meijerink MR, van den Eert-Wegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102(5):803-809.
16. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RE-CIST and Choi criteria. Radiology 2009;251(2): 447-456.
17. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 2006;9(3):125-132.
18. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711.
19. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepato-cellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616-623.
20. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430.
21. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
22. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fuorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20(2): 379-387.
23. Brücher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233(3):300-309.
24. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S-150S.
25. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985;3(5):637-640.
26. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-586.
27. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412-7420.
28. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30(1):1-15.